| Literature DB >> 35740057 |
Malik Waseem Abbas1, Mazhar Hussain1, Saeed Akhtar2, Tariq Ismail2, Muhammad Qamar2, Zahid Shafiq1, Tuba Esatbeyoglu3.
Abstract
Tribulus terrestris L. belongs to the family Zygophyllaceae and integral part of various ancient medicinal systems including Chinese, Indian, and European to combat various health ailments. The aim of the present study was to assess the phytochemical constituents, in vitro antioxidant activity using DPPH, FRAP, and H2O2 assays, in vitro anticancer activity using MTT assay, and in vitro and in vivo anti-inflammatory properties of T. terrestris. The acute and sub-acute toxicity of extracts exhibiting most biological potential was examined using murine models. Liquid-liquid partitioning followed by RP-HPLC sub-fraction of crude extract was performed. After that, ESI-MS/MS analysis was done for the timid identification of bioactive metabolites responsible for bioactivities of sub-fractions and HPLC analysis to quantify the compounds using external standards. Among all extracts, T. terrestris methanol extract was noted to hold maximum phenolic (341.3 mg GAE/g) and flavonoid (209 mg QE/g) contents, antioxidant activity in DPPH (IC50 71.4 µg/mL), FRAP (35.3 mmol/g), and H2O2 (65.3% inhibition) assays, anti-inflammatory activities in vitro at 400 µg/mL (heat-induced hemolysis, % inhibition 68.5; egg albumin denaturation, % inhibition 75.6%; serum albumin denaturation, % inhibition 80.2), and in vivo at 200 mg/kg (carrageenan-induced paw edema, % inhibition 69.3%; formaldehyde-induced paw edema, % inhibition 71.3%) and anticancer activity against breast cancer cell (MCF-7) proliferation (IC50 74.1 µg/mL). Acute and sub-acute toxicity studies recorded with no change in body weight, behavior, hematological, serum, and histopathological parameters in treated rats with T. terrestris methanol extracts when compared to control group. Fraction B obtained through liquid-liquid partitioning resulted in more bioactive potential as compared to the parent methanol extract. RP-HPLC analysis of fraction B resulted with four sub-fractions (TBTMF1-TBTMF4), wherein TBTMF3 delineated notable bioactive capabilities as compared to other fractions and parent methanol extract. ESI-MS/MS analysis of TBTMF3 resulted with tentative identification of myricetin, rutin, liquitrigenin, physcion, and protodioscin. It can be stated that T. terrestris is a potential bearing herb and findings of current study further verify the claims made in ancient medicinal systems. However, after investigation of each identified compound, it must be considered for drug discovery.Entities:
Keywords: ESI-MS/MS; RP–HPLC; antioxidant; bioassay-guided fractionation; cancer; inflammation; liquitrigenin; myricetin; phytochemicals; rutin; toxicity
Year: 2022 PMID: 35740057 PMCID: PMC9219970 DOI: 10.3390/antiox11061160
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
In vitro antioxidant activities of three different T. terrestris extracts compared to control samples.
| Assay | DCM | Methanol | 70% Aqueous Methanol | Ascorbic Acid | Quercetin |
|---|---|---|---|---|---|
| FRAP | 4.10 ± 0.2 | 35.3 ± 0.5 | 21.5 ± 1.01 | 51.0 ± 0.02 | 62.0 ± 0.02 |
| DPPH | 332.3 ± 2.5 | 71.4 ± 1.1 | 141.2 ± 0.01 | 29.1 ± 0.02 | 25.4 ± 0.01 |
| H2O2 | 12.5 ± 0.66 | 65.3 ± 0.53 | 34.6 ± 0.83 | 79 ± 0.02 | 84 ± 0.05 |
Values are means ± S.D. DCM; dichloromethane.
In vitro anti-inflammatory activity of T. terrestris crude extracts at 400 µg/mL.
| Treatment | Membrane | Serum Albumin | Egg Albumin |
|---|---|---|---|
| % Inhibition | |||
| Control | NI | NI | NI |
| Methanol extract | 68.5 *** | 80.2 *** | 75.6 *** |
| 70% aqueous methanol extract | 35.9 * | 48.3 ** | 43.2 ** |
| Dichloromethane extract | NA | NA | NA |
| Diclofenac sodium | 89.3 **** | 97.8 **** | 91.5 **** |
Values are means ± S.D. of three measurements. NA, No activity. NI, No inhibition. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Figure 1(A) Carrageenan-induced and (B) formaldehyde-induced paw edema inhibition. Values are mean ± SEM of three readings. The standard drug (Indomethacin) exhibited potent inhibition of 86.3% (p < 0.0001) and 89.3% (p < 0.0001) against carrageenan and formaldehyde intoxicated paw edema at 100 mg/kg, respectively when compared to control (normal saline = 0% inhibition). On the other hand, dichloromethane and 70% aqueous methanol extracts induced moderate to non-substantial inhibition in both assays.
In vitro anticancer activity of the T. terrestris crude extracts at 10 µg/mL, 100 µg/mL, 1000 µg/mL (IC50 µg/mL).
| MCF-7 | HeLa | SK-OV-3 | NCI-H522 | |
|---|---|---|---|---|
| Methanol | 74.1 | 221.2 | 89.4 | 102.1 |
| 70% aqueous methanol | 176.4 | 343.1 | 256.2 | 441.8 |
| Dichloromethane | NA | NA | NA | NA |
| Methotrexate (standard drug) | 0.87 | 0.92 | 0.91 | 0.88 |
The values are means ± SE and shown as IC50 µg/mL. Each value is expressed as mean of triplicate treatments. HeLa (cervical cancer cell line), MCF-7 (breast cancer cell line), SK-OV-3 (ovary carcinoma), NCI-H522 (lung cancer cell line). NA, No activity.
Acute and subacute toxicity assessment of Tribulus terrestris methanol extract using in vivo model.
| Parameters | Control Group | Acute Toxicity (14 days) | Subacute Toxicity (28 days) | ||
|---|---|---|---|---|---|
| Normal Saline | 2000 mg/kg | 3000 mg/kg | 500 mg/kg | 1000 mg/kg | |
| Body weight (g) | 197.00 ± 8.00 | 210 ± 3.59 | 205 ± 4.50 | 194 ± 10.2 | 223 ± 11.6 |
|
| |||||
| Heart (g) | 0.59 ± 0.22 | 0.66 ± 0.20 | 0.64 ± 0.05 | 0.58 ± 0.20 | 0.73 ± 0.10 |
| Paired Lungs (g) | 2.12 ± 1.10 | 2.22 ± 0.82 | 2.15 ± 0.80 | 2.09 ± 1.18 | 2.42 ± 1.22 |
| Liver (g) | 7.89 ± 1.35 | 8.10 ± 2.90 | 7.92 ± 1.22 | 7.79 ± 2.15 | 8.50 ± 2.90 |
| Spleen (g) | 0.44 ± 0.05 | 0.52 ± 0.01 | 0.49 ± 0.10 | 0.42 ± 0.20 | 0.62 ± 0.30 |
|
| |||||
| White blood cells (105/µL) | 3.35 ± 0.22 | 4.29 ± 0.30 | 4.53 ± 0.14 | 3.69 ± 0.32 | 3.99 ± 1.89 |
| Neutrophils (%) | 38.91 ± 1.10 | 62.91 ± 2.22 | 64.01 ± 2.40 | 60.61 ± 2.34 | 55.52 ± 27.21 |
| Lymphocytes (%) | 43.39 ± 2.30 | 74.91 ± 4.30 | 78.60 ± 3.40 | 63.96 ± 4.93 | 66.87 ± 33.48 |
| Eosinophils (%) | 0.92 ± 0.11 | 1.46 ± 0.10 | 1.63 ± 0.08 | 1.19 ± 0.11 | 1.70 ± 0.67 |
| Red blood cells (106/µL) | 8.90 ± 1.05 | 16.05 ± 1.20 | 17.00 ± 1.65 | 12.91 ± 2.40 | 17.03 ± 7.80 |
| Hemoglobin (g/dl) | 12.92 ± 1.20 | 26.05 ± 1.95 | 24.92 ± 2.10 | 20.02 ± 2.79 | 22.90 ± 12.49 |
| Hematocrit (%) | 46.50 ± 3.60 | 70.83 ± 3.70 | 70.43 ± 2.92 | 59.77 ± 4.24 | 64.72 ± 30.80 |
| MCV (f/L) | 56.20 ± 7.51 | 99.09 ± 7.50 | 97.62 ± 5.93 | 77.66 ± 8.59 | 85.27 ± 43.41 |
| MCH (pg) | 17.91 ± 1.55 | 28.78 ± 0.25 | 27.10 ± 2.10 | 22.90 ± 0.80 | 25.76 ± 12.18 |
| MCHC (%) | 30.93 ± 1.04 | 43.92 ± 1.10 | 48.90 ± 0.70 | 40.06 ± 1.10 | 43.01 ± 17.80 |
| Platelets (105/µL) | 7.45 ± 0.10 | 11.05 ± 0.40 | 10.91 ± 1.25 | 9.12 ± 1.25 | 11.35 ± 6.20 |
|
| |||||
| Total Protein (g/dL) | 6.59 ± 2.25 | 7.31 ± 1.20 | 8.01 ± 0.90 | 5.69 ± 2.16 | 7.50 ± 4.02 |
| Albumin (g/dL) | 3.01 ± 1.25 | 3.70 ± 0.71 | 3.91 ± 0.45 | 3.15 ± 0.80 | 3.72 ± 1.95 |
| Albumin/Globulin ratio | 1.80 ± 0.28 | 3.55 ± 0.20 | 3.20 ± 0.25 | 3.60 ± 0.5 | 3.19 ± 0.75 |
| Lactate Dehydrogenase (U/L) | 2230 ± 0.26 | 3166 ± 271.0 | 3085.8 ± 214.1 | 2975.7 ± 310.4 | 3290.4 ± 231.5 |
| Asparate Transaminase (U/L) | 142.0 ± 271.0 | 191.3 ± 10.10 | 187.4 ± 7.98 | 175.1 ± 11.57 | 179.2 ± 29.34 |
| Alanine Transaminase (U/L) | 25.30 ± 10.10 | 59.51 ± 5.50 | 57.66 ± 4.35 | 48.47 ± 6.30 | 53.80 ± 7.96 |
| Alkaline Phosphatase (U/L) | 379.0 ± 9.10 | 418.0 ± 13.10 | 417.0 ± 10.82 | 391.2 ± 16.91 | 397.5 ± 19.02 |
| Total bilirubin (mg/dL) | 0.34 ± 0.12 | 0.70 ± 0.10 | 1.42 ± 0.04 | 0.39 ± 0.06 | 2.19 ± 1.29 |
| Creatinine (mg/dL) | 1.91 ± 0.09 | 3.14 ± 0.20 | 3.43 ± 0.24 | 2.59 ± 0.07 | 3.26 ± 0.79 |
| Uric Acid (mg/dl) | 0.91 ± 12.3 | 1.62 ± 0.12 | 2.19 ± 0.04 | 1.36 ± 0.12 | 2.91 ± 35.02 |
| Total Cholesterol (mg/dl) | 50.91 ± 3.15 | 85.00 ± 4.20 | 84.01 ± 2.90 | 70.12 ± 6.13 | 77.02 ± 67.31 |
| Triglycerides (mg/dl) | 117.2 ± 5.12 | 189.2 ± 8.12 | 182.6 ± 9.03 | 155.0 ± 9.71 | 154.2 ± 80.19 |
| Potassium (mmol/L) | 2.54 ± 1.42 | 5.39 ± 2.20 | 5.53 ± 2.43 | 4.54 ± 0.13 | 5.19 ± 1.11 |
| Chloride (mmol/L) | 70.24 ± 18.31 | 144.2 ± 19.22 | 145.2 ± 14.70 | 111.4 ± 21.81 | 152.0 ± 12.40 |
| Sodium (mmol/L) | 136.1 ± 17.20 | 190.4 ± 17.22 | 192.0 ± 13.42 | 150.0 ± 21.52 | 183.0 ± 64.61 |
TBTME, Tribulus terrestris methanol extract. MCV, Mean corpuscular volume. MCH, Mean corpuscular hemoglobin. MCHC, Mean corpuscular hemoglobin concentration.
Figure 2Histopathology results of acute and subacute toxicity of T. terrestris methanol extract.
Biological activities of T. terrestris liquid–liquid partitioned fractions compared to control samples.
| Assays | Fraction | Fraction | Fraction | Ascorbic Acid | Quercetin | Diclofenac Sodium | Methotrexate |
|---|---|---|---|---|---|---|---|
|
| |||||||
| FRAP (mmol/g) | NA | 45.2 ± 0.1 | 17.2 ± 0.10 | 50.9 ± 0.20 | 61.9 ± 0.05 | - | - |
| DPPH (IC50 µg/mL) | NA | 56.2 ± 1.1 | 91.9 ± 0.01 | 30.2 ± 0.05 | 24.9 ± 0.10 | - | - |
| H2O2 (%) | NA | 68.0 ± 0.2 | 32.1 ± 0.5 | 79.0 ± 0.02 | 84.0 ± 0.05 | - | - |
|
| |||||||
| Heat-induced hemolysis | NA | 74.1 *** | 36.9 ± 0.10 * | - | - | 89.3 **** | - |
| Egg albumin denaturation | NA | 77.9 *** | 39.6 ± 0.2 * | - | - | 91.5 **** | - |
| Serum albumin denaturation | NA | 83.5 *** | 52.1 ± 0.10 * | - | - | 97.8 **** | - |
|
| |||||||
| MCF-7 | NA | 65.2 | 122.8 | - | - | - | 0.80 |
| HeLa | NA | 223.6 | NA | - | - | - | 0.92 |
| SK-OV-3 | NA | 81.3 | 231.8 | - | - | - | 0.92 |
| NCI-H522 | NA | 111.9 | 174.9 | - | - | - | 0.88 |
Values are means ± S.D., FRAP, Ferric reducing antioxidant power assay. DPPH, 2,2-diphenyl-1-picrylhydrazyl. H2O2, Hydrogen peroxide. NA, No activity. (* p < 0.05, *** p < 0.001, **** p < 0.0001)
Biological activities of RP–HPLC separated sub-fractions of the T. terrestris methanol extract.
| Assays | TBTMF1 | TBTMF2 | TBTMF3 | TBTMF4 | Ascorbic Acid | Quercetin | Diclofenac Sodium | Methotrexate |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| FRAP (mmol/g) | NA | 26.1 ± 0.3 | 49.1 ± 0.1 | 38.8 ± 1.1 | 51 ± 0.02 | 62 ± 0.02 | - | - |
| DPPH (IC50 µg/mL) | NA | 96.6 ± 0.2 | 41.9 ± 1.1 | 104.6 ± 0.1 | 29.1 ± 0.02 | 25.4 ± 0.01 | - | - |
| H2O2 (%) | NA | 28.1 ± 1.1 | 71.2 ± 0.5 | 17.3 ± 0.2 | 79 ± 0.02 | 84 ± 0.05 | - | - |
|
| ||||||||
| Membrane stabilization | NA | 33.2 | 76.1 | 29.5 | - | - | 89.3 | - |
| Egg albumin denaturation | NA | 37.8 | 81.9 | 30.8 | - | - | 91.5 | - |
| Serum albumin denaturation | NA | 44.8 | 85.2 | 34.5 | - | - | 97.8 | - |
|
| ||||||||
| Breast cancer | NA | 281.4 | 43.2 | 331.9 | - | - | - | 0.87 |
| Cervical cancer (HeLa) | NA | 441.9 | 142.5 | NA | - | - | - | 0.92 |
| Ovary carcinoma (SK-OV-3) | NA | NA | 88.4 | 241.9 | - | - | - | 0.96 |
| Lung cancer (NCI-H522) | NA | 321.4 | 298.6 | NA | - | - | - | 0.88 |
TBTMF. T. terrestris methanol fraction, - Not evaluated.
Figure 3Overlay of HPLC-chromatograms of standards (blue) and the TBTMF3 fraction (red) recorded at 280 nm by HPLC-DAD.
Quantification of rutin, protodioscin, and myricetin from T. terrestris RP–HPLC sub-fraction TBTMF3.
| Compound Name | LOD | LOQ |
| Rt min | Concentration |
|---|---|---|---|---|---|
| Rutin | 1.70 | 4.90 | 0.9998 | 4.9 | 2.19 |
| Protodioscin | 1.10 | 3.20 | 0.9986 | 5.1 | 11.2 |
| Myricetin | 1.90 | 5.60 | 0.9999 | 22.3 | 4.2 |
Shown are mean values of three measurements, Limit of quantification (LOQ), Limit of detection (LOD), Coefficient of regression (r2), time of retention (Rt), Tribulus Terrestris methanolic fraction 3 (TBTMF3).